Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.
Saved in:
| Title: | Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma. |
|---|---|
| Authors: | Yonemoto, Takuya1 (AUTHOR), Ogasawara, Sadahisa1 (AUTHOR) ogasawaras@chiba-u.jp, Kanogawa, Naoya1 (AUTHOR), Miwa, Chihiro1 (AUTHOR), Fujiya, Makoto1 (AUTHOR), Tsuchiya, Takahiro1 (AUTHOR), Sawada, Midori1 (AUTHOR), Akatsuka, Teppei1 (AUTHOR), Izai, Ryo1 (AUTHOR), Yumita, Sae1 (AUTHOR), Nakagawa, Miyuki2 (AUTHOR), Okubo, Tomomi3 (AUTHOR), Koroki, Keisuke1 (AUTHOR), Inoue, Masanori1 (AUTHOR), Nakamura, Masato1 (AUTHOR), Kondo, Takayuki1 (AUTHOR), Nakamoto, Shingo1 (AUTHOR), Itokawa, Norio3 (AUTHOR), Atsukawa, Masanori3 (AUTHOR), Itobayashi, Ei2 (AUTHOR) |
| Source: | Hepatology Research. May2025, Vol. 55 Issue 5, p718-729. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
